


HEALTHCARE

Pharmaceutical Outsourcing Strategies

Market expansion, offshoring and strategic management
in the CRO and CMO marketplace

By Alison Sahoo

 [Table of Contents](#)

Alison Sahoo

Alison Sahoo is a pharmaceutical industry analyst with more than 10 years of experience researching the development of medicines and medical devices. She holds a B.S. in Physics from McGill University and an M.B.A. in International Business from Rutgers University.

Copyright © 2006 Business Insights Ltd
This Management Report is published by Business Insights Ltd. All rights reserved.
Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

Table of Contents

Pharmaceutical Outsourcing Strategies

Executive Summary	10	
The pharmaceutical outsourcing market	10	
Drivers of pharmaceutical outsourcing	11	
Emerging fields of outsourcing	12	
Offshore outsourcing	13	
Optimizing the outsourcing process	14	
The future of pharmaceutical outsourcing	15	
Chapter 1	The pharmaceutical outsourcing market	18
Summary		18
The concept of outsourcing		19
Approaches to outsourcing		21
Outsourcing research and development		23
Services offered by CROs		24
The role of CROs in clinical trials		27
The role of CROs in pre-clinical trials		28
Outsourcing manufacturing		29
Services offered by CMOs		31
Sizing the CRO and CMO markets		34
Overview of the CRO market		35
Sizing the CRO market		37
Overview of the CMO market		38
Sizing the CMO market		39
Conclusion		41

Chapter 2 Drivers of pharmaceutical outsourcing 44

Summary	44
Introduction	45
Outsourcing research and development	47
Drivers of outsourcing research and development	47
Increased complexity of clinical trials and regulatory submissions	47
Rising data requirements	49
Cost savings	50
Minimizing time to market	51
Advantages and disadvantages of using CROs	53
Long term cost savings vs. high short term expenses	54
Personnel customization vs. CRO high staff turnover	55
Flexibility vs. loss of control	56
Outsourcing manufacturing	57
Drivers of outsourcing manufacturing	57
Cost savings	57
Increased supply of contract manufacturing services	58
Advantages and disadvantages of using CMOs	59
Long term cost savings vs. high short term expenses	60
Lead time savings vs. relationship management time losses	62
Access to expertise vs. quality control	63
Conclusion	63

Chapter 3 Emerging fields of outsourcing 66

Summary	66
Introduction	67
Drug discovery	68
Specialized discovery service providers	69
Case study: WuXi PharmaTech	71
Contract research organizations	72
Contract manufacturing organizations	72
Biotech	73
Biotech contractors	73
Contract research organizations	74
Contract manufacturing organizations	75
Case study: Ortho Biotech Products	77
Distribution	79
The mechanics of pharmaceutical distribution	79
Wholesaler distribution	80
Direct distribution	80
Agency distribution	80

Mail order	81
Self-distribution	81
Parallel importing	82
Pharmacy benefit management	82
Outsourcing distribution	83
Conclusion	84

Chapter 4 Offshore outsourcing 86

Summary	86
Introduction	87
Offshore outsourcing of contract research	89
Offshore outsourcing of contract manufacturing	89
Eastern Europe	91
Contract research in Eastern Europe	92
CRO developments in Eastern Europe	94
Contract manufacturing in Eastern Europe	95
CMO developments in Eastern Europe	95
India	96
Contract research in India	96
Patent issues in India	99
CRO developments in India	99
Contract manufacturing in India	100
CMO developments in India	101
Early stage collaborations	102
China	102
Contract research in China	103
Patent issues in China	105
CRO developments in China	106
Contract manufacturing in China	107
CMO developments in China	108
Offshore outsourcing market	109
Case study: Wyeth	111
Conclusion	112

Chapter 5 Optimizing the outsourcing process 114

Summary	114
Introduction	115
Outsourcing agreements	115
Contract research agreements	116

Case study: Pharmaceutical Product Development (PPDI)	117
Contract manufacturing agreements	120
Assessing sourcing needs, opportunity and difficulty	121
Assessing quality vs. cost savings	123
Strategic management of outsourcing	128
Selecting outsourcing partners	128
Managing partnerships	130
Timelines and preventing overruns	131
Risks and mitigation	133
Confidentiality and intellectual property risks	133
Personnel risks	134
Company volatility risks	134
Production risks	135
Case study: Novartis	136
Conclusion	137

Chapter 6 The future of pharmaceutical outsourcing 140

Summary	140
Introduction	141
Pharmaceutical contract research alliances	141
eTechnology	143
Internet-based recruitment of clinical trial patients	144
Electronic data capture, storage and retrieval	145
Clinical trial data	145
Central laboratory data	146
<i>In silico</i> technologies	147
Case study: Entelos	147
Virtual drug development companies	148
Non-profit virtual drug development groups	153
Big pharma virtual drug development groups	153
Case study: GlaxoSmithKline	154
Conclusion	156

Chapter 7 Appendix 158

Index	158
--------------	------------

List of Figures

Figure 1.1:	Degree of outsourcing to be conducted by pharmaceutical outsourcers in 2006	20
Figure 1.2:	Importance of contract organization characteristics to pharmaceutical outsourcers	21
Figure 1.3:	In-house versus outsourced expenditure on R&D and manufacturing, 2000-2005 (\$bn)	34
Figure 1.4:	Contract research revenues by segment, 2005 (\$m)	36
Figure 1.5:	Revenues of leading CROs, 2005 (\$m)	37
Figure 1.6:	CRO market growth, 2005-2010 (\$m)	38
Figure 1.7:	Contract manufacturing revenues by segment, 2005 (\$m)	40
Figure 1.8:	CMO market growth, 2005 - 2010 (\$m)	40
Figure 2.9:	Drivers of CRO and CMO usage, 2005	46
Figure 2.10:	US R&D spending versus new drug approvals, 1995-2004	52
Figure 2.11:	Potential advantages and disadvantages of using a CRO	53
Figure 2.12:	Potential advantages and disadvantages of using a CMO	60
Figure 3.13:	Importance of different characteristics in biotech CMO selection, 2005	77
Figure 4.14:	Relative pharmaceutical research and manufacturing capabilities in India, China and Eastern Europe, 2005	90
Figure 4.15:	Contract research revenues by region, 2005 (\$m)	109
Figure 4.16:	Contract manufacturing revenues by region, 2005 (\$m)	110
Figure 5.17:	Outsourcing difficulty vs. opportunity	123
Figure 5.18:	Impact of low prices on outsourcing outcomes	125
Figure 6.19:	Characteristics of different contractor relationships	154

List of Tables

Table 1.1:	Summary of drug testing objectives by phase	26
Table 2.2:	Recent drug recalls, 2000-2006	48
Table 3.3:	Capabilities of leading CROs and CMOs in emerging areas	67
Table 3.4:	Selected specialty drug discovery contractors	70
Table 4.5:	Advantages and disadvantages of international outsourcing	88
Table 4.6:	Eastern European operations of leading CROs	94
Table 4.7:	US FDA new drug application data generated from India	98
Table 5.8:	Typical opportunities and difficulties of outsourcing	122
Table 5.9:	Selected pharmaceutical manufacturing violations	127
Table 5.10:	Reasons for time and budget overruns	132
Table 6.11:	Relationships between virtual pharma sponsor and contractors	150
Table 6.12:	Selected virtual drug development companies	152